Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Long-term safety & efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia

Mehran Karimi • 12 Jul 2022
ISTH 2022
Non-Malignant Sickle Cell Disease Thalassemia Hydroxyurea

Mehran Karimi, MD, Hematology Research Center Shiraz University of Medical Sciences, Shiraz, Iran, comments on the use and long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia, highlighting the mechanism of action of this drug. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Mehran Karimi

5:42
Improving the QoL of patients with hemophilia with inhibitors
Mehran Karimi • 12 Jul 2022

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals